Recently, Deqi Pharmaceutical announced the completion of the 120 million US dollar B round of financing. This round of financing was jointly led by Boyu Capital and Fangyuan Capital. Xinji, WuXi PharmaTech Venture Capital Fund and Taikang participated in the investment. The existing investors are enlightened. Venture Capital and Taifu Capital continued to follow suit.
Dejian Pharmaceutical founder & Chairman Mei Jianming said: This round of financing will be mainly used to promote the continuous research and development and commercialization of ATG-008, ATG-010 and other products, expand the research and commercialization team, and further through independent research and development and external cooperation. The combination of methods to expand product pipelines, to create a comprehensive development platform for the development of new tumors. In addition, the company has completed the preparation workshop of 15,792 square meters in Shaoxing, China. It is currently undergoing GMP renovation, and the future production capacity can meet the production needs of the above products. At the same time, a commercialization team is being set up to build a professional market for the above products. Marketing system.
It is reported that Deqi Medicine is a technology-based pharmaceutical company specializing in the research, development, production and sales of innovative drugs. It aims to provide the most advanced oncology drug treatment solutions for patients in Asia and around the world, and develop innovative therapies to solve global unmet needs. Medical needs.
Fire Alarm By Garage,Smoke Alarms By Garage,Smoke Alarm By Garage,Garage Smoke Alarms
Guangdong Isafenest Co.,Ltd. , https://www.isfenest.com